Some degree of coronavirus transmission through air likely: Anthony Fauci

Fauci on Thursday had said it was a "reasonable assumption" that airborne transmission was occurring even though there was not a lot of solid evidence behind it

Coronavirus, medical staff, Rapid antigen testing, RAT
The United States has poured billions of dollars into vaccine efforts at Johnson & Johnson, Moderna, Novavax and AstraZeneca.
Reuters
2 min read Last Updated : Jul 10 2020 | 10:03 PM IST
The new coronavirus is likely spreading through the air to some degree, the top US infectious disease official said on Friday, one day after the World Health Organization urged further studies on the ways the virus is transmitted.

"Still some question about aerosol but likely some degree of aerosol," Anthony Fauci, the head of the US National Institute of Allergy and Infectious Diseases, said by video during a panel session at a Covid-19 conference organized by the International AIDS Society.

Fauci on Thursday had said it was a "reasonable assumption" that airborne transmission was occurring even though there was not a lot of solid evidence behind it. The WHO urged more studies on the issue.

The number of cases in the United States has surged to more than 3 million as states that quickly reopened bars and restaurants have reported sharp increases.


Fauci said that to battle the global virus, there needed to be multiple vaccine candidates. Vaccine makers are aiming to have hundreds of millions of doses ready for early next year and as many as 1 billion in some cases, he said.

"The companies that we are dealing with are already in discussions to start gearing up to make hundreds of millions of doses and a couple of the companies are promising that they would have a billion doses within a year or so after," Fauci said.

The United States has poured billions of dollars into vaccine efforts at Johnson & Johnson, Moderna, Novavax and AstraZeneca.

J&J has said it is aiming for 1 billion doses. Pfizer and BioNTech are also pursuing a vaccine and have said they aim to have 1.2 billion doses by the end of 2021.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineUnited States

Next Story